McDermott Will & Emery advised Egle Therapeutics on the deal. Gide advised the pool of investors, while Morgan, Lewis & Bockius advised Takeda Ventures.
Egle Therapeutics, which is a spin off of Institut Curie, an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, closed its €40 million Series A financing round.
The round has been co-led by a pool of investors including LSP and BPI. Fund+, BioQube and Takeda Ventures, Inc. also participated in the round.
The new capital will be used primarily to advance the 2 lead assets into clinics, and further strengthen the internal drug pipeline.
The McDermott team who advised Egle Therapeutics and its managers comprised Emmanuelle Trombe (Picture) and Anne-France Moreau, partners, and Ludivine Rabreau, associate.
The Gide team included Pierre Karpik and Donald Davy.
Morgan, Lewis & Bockius UK advised Takeda Ventures with Olivier Chambord.
Involved fees earner: Donald Davy – Gide Loyrette Nouel; Pierre Karpik – Gide Loyrette Nouel; Anne-France Moreau – McDermott Will & Emery; Ludivine Rabreau – McDermott Will & Emery; Emmanuelle Trombe – McDermott Will & Emery; Olivier Chambord – Morgan Lewis & Bockius;